Psychological factors associated with response to treatment in rheumatoid arthritis

Current Pharmaceutical Design

Volumn 21, Issue 2, 2015, Pages 257-269

  Santiago, T ^a   Geenen, R ^b   Jacobs, J W G ^c   Da Silva, J A P ^a  

^a CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Coping; Depression; Placebo; Psychological adjustment; Psychological factors; Psychoneuroimmunology; Rheumatoid arthritis; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIRHEUMATIC AGENT; ANTIINFLAMMATORY AGENT;

ANXIETY DISORDER; ARTICLE; COGNITION; COPING BEHAVIOR; DEPRESSION; DISEASE ACTIVITY; DISTRESS SYNDROME; EXPECTATION; FATIGUE; FUNCTIONAL DISEASE; HUMAN; INTERPERSONAL COMMUNICATION; LONG TERM CARE; PAIN; PATIENT COMPLIANCE; PATIENT EDUCATION; PERSONALITY; PLACEBO EFFECT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SELF CARE; SLEEP DISORDER; SOCIAL ENVIRONMENT; SOCIAL SUPPORT; STRESS; THERAPY EFFECT; TREATMENT RESPONSE; WELLBEING; ARTHRITIS, RHEUMATOID; PSYCHOLOGY;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; HUMANS;

EID: 84925879411     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140825124755     Document Type: Article

References (175)

1. McWilliams LA, Clara IP, Murphy PD, Cox BJ, Sareen J. Associations between arthritis and a broad range of psychiatric disorders: findings from a nationally representative sample. J Pain, 2008; 9: 37-44.
2. Dickens C, McGowan L, Clark-Carter D, Creed F. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med, 2002; 64: 52-60.
3. Covic T, Tyson G, Spencer D, Howe G. Depression in rheumatoid arthritis patients: demographic, clinical, and psychological predictors. J Psychosom Res, 2006; 60: 469-76.
4. Geenen R, Newman S, Bossema ER, Vriezekolk JE, Boelen PA. Psychological interventions for patients with rheumatic diseases and anxiety or depression. Best Pract Res Clin Rheumatol, 2012; 26: 305-19.
5. Isik A, Koca SS, Ozturk A, Mermi O. Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol, 2007; 26: 872-8.
6. Overman CL, Bossema ER, van Middendorp H, Wijngaards-de Meij L, Verstappen SM, Bulder M, Jacobs JW, Bijlsma JW, Geenen R. The prospective association between psychological distress and disease activity in rheumatoid arthritis: a multilevel regression analysis. Ann Rheum Dis, 2012; 71: 192-7.
7. Wiltink J, Beutel ME, Till Y, Ojeda FM, Wild PS, Munzel T, Blankenberg S, Michal M. Prevalence of distress, comorbid conditions and well being in the general population. J Affect Disord, 2011; 130: 429-37.
8. Dickens C, Creed F. The burden of depression in patients with rheumatoid arthritis. Rheumatology (Oxford), 2001; 40: 1327-30.
9. Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. Curr Psychiatry Rep, 2008; 10: 258-64.
10. Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A. Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis. Rheumatology (Oxford), 2011; 50: 401-9.
11. Hider SL, Tanveer W, Brownfield A, Mattey DL, Packham JC. Depression in RA patients treated with anti-TNF is common and under-recognized in the rheumatology clinic. Rheumatology (Oxford), 2009; 48: 1152-4.
12. Mattey DL, Dawes PT, Hassell AB, Brownfield A, Packham JC. Effect of psychological distress on continuation of anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. J Rheumatol, 2010; 37: 2021-4.
13. Geenen R, Van Middendorp H, Bijlsma JW. The impact of stressors on health status and hypothalamic-pituitary-adrenal axis and autonomic nervous system responsiveness in rheumatoid arthritis. Ann N Y Acad Sci, 2006; 1069: 77-97.
14. Potter PT, Zautra AJ. Stressful life events' effects on rheumatoid arthritis disease activity. J Consult Clin Psychol, 1997; 65: 319-23.
15. Affleck G, Urrows S, Tennen H, Higgins P, Pav D, Aloisi R. A dual pathway model of daily stressor effects on rheumatoid arthritis. Ann Behav Med, 1997; 19: 161-70.
16. Zautra AJ, Yocum DC, Villanueva I, Smith B, Davis MC, Attrep J, Irwin M. Immune activation and depression in women with rheumatoid arthritis. J Rheumatol, 2004; 31: 457-63.
17. Evers AW, Kraaimaat FW, Geenen R, Jacobs JW, Bijlsma JW. Stress-vulnerability factors as long-term predictors of disease activity in early rheumatoid arthritis. J Psychosom Res, 2003; 55: 293-302.
18. Costa PT, Jr. Influence of the normal personality dimension of neuroticism on chest pain symptoms and coronary artery disease. Am J Cardiol, 1987; 60: 20j-26j.
19. Affleck G, Urrows S, Tennen H, Higgins P. Daily coping with pain from rheumatoid arthritis: patterns and correlates. Pain, 1992; 51: 221-9.
20. Persson LO, Sahlberg D. The influence of negative illness cognitions and neuroticism on subjective symptoms and mood in rheumatoid arthritis. Ann Rheum Dis, 2002; 61: 1000-6.
21. Hyphantis TN, Bai M, Siafaka V, Georgiadis AN, Voulgari PV, Mavreas V, Drosos AA. Psychological distress and personality traits in early rheumatoid arthritis: A preliminary survey. Rheumatol Int, 2006; 26: 828-36.
22. Vriezekolk JE, van Lankveld WG, Geenen R, van den Ende CH. Longitudinal association between coping and psychological distress in rheumatoid arthritis: a systematic review. Ann Rheum Dis, 2011; 70: 1243-50.
23. Somers TJ, Keefe FJ, Pells JJ, Dixon KE, Waters SJ, Riordan PA, Blumenthal JA, McKee DC, LaCaille L, Tucker JM, Schmitt D, Caldwell DS, Kraus VB, Sims EL, Shelby RA, Rice JR. Pain catastrophizing and pain-related fear in osteoarthritis patients: relationships to pain and disability. J Pain Symptom Manage, 2009; 37: 863-72.
24. Wise BL, Niu J, Zhang Y, Wang N, Jordan JM, Choy E, Hunter DJ. Psychological factors and their relation to osteoarthritis pain. Osteoarthritis Cartilage, 2010; 18: 883-7.
25. Kim SC, Yelin E, Tonner C, Solomon DH. Changes in use of disease modifying anti-rheumatic drugs for rheumatoid Arthritis in the U.S. for the period 1983-2009. Arthritis Care Res (Hoboken), 2013.
26. Mattey DL, Brownfield A, Dawes PT. Relationship between packyear history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J Rheumatol, 2009; 36: 1180-7.
27. Lu B, Solomon DH, Costenbader KH, Keenan BT, Chibnik LB, Karlson EW. Alcohol consumption and markers of inflammation in women with preclinical rheumatoid arthritis. Arthritis Rheum, 2010; 62: 3554-9.
28. Maxwell JR, Gowers IR, Moore DJ, Wilson AG. Alcohol consumption is inversely associated with risk and severity of rheumatoid arthritis. Rheumatology (Oxford), 2010; 49: 2140-6.
29. Kallberg H, Jacobsen S, Bengtsson C, Pedersen M, Padyukov L, Garred P, Frisch M, Karlson EW, Klareskog L, Alfredsson L. Alcohol consumption is associated with decreased risk of rheumatoid arthritis: results from two Scandinavian case-control studies. Ann Rheum Dis, 2009; 68: 222-7.
30. Van den Ende CH, Vliet Vlieland TP, Munneke M, Hazes JM. WITHDRAWN: Dynamic exercise therapy for treating rheumatoid arthritis. Cochrane Database Syst Rev, 2008: Cd000322.
31. de Jong Z, Munneke M, Zwinderman AH, Kroon HM, Jansen A, Ronday KH, van Schaardenburg D, Dijkmans BA, Van den Ende CH, Breedveld FC, Vliet Vlieland TP, Hazes JM. Is a long-term high-intensity exercise program effective and safe in patients with rheumatoid arthritis? Results of a randomized controlled trial. Arthritis Rheum, 2003; 48: 2415-24.
32. Hurkmans E, van der Giesen FJ, Vliet Vlieland TP, Schoones J, Van den Ende EC. Dynamic exercise programs (aerobic capacity and/or muscle strength training) in patients with rheumatoid arthritis. Cochrane Database Syst Rev, 2009: Cd006853.
33. Brekke M, Hjortdahl P, Kvien TK. Changes in self-efficacy and health status over 5 years: a longitudinal observational study of 306 patients with rheumatoid arthritis. Arthritis Rheum, 2003; 49: 342-8.
34. Taal E, Rasker JJ, Seydel ER, Wiegman O. Health status, adherence with health recommendations, self-efficacy and social support in patients with rheumatoid arthritis. Patient Educ Couns, 1993; 20: 63-76.
35. Barlow JH, Cullen LA, Rowe IF. Educational preferences, psychological well-being and self-efficacy among people with rheumatoid arthritis. Patient Educ Couns, 2002; 46: 11-9.
36. Riemsma RP, Rasker JJ, Taal E, Griep EN, Wouters JM, Wiegman O. Fatigue in rheumatoid arthritis: the role of self-efficacy and problematic social support. Br J Rheumatol, 1998; 37: 1042-6.
37. Groarke A, Curtis R, Coughlan R, Gsel A. The role of perceived and actual disease status in adjustment to rheumatoid arthritis. Rheumatology (Oxford), 2004; 43: 1142-9.
38. Smarr KL, Parker JC, Wright GE, Stucky-Ropp RC, Buckelew SP, Hoffman RW, O'Sullivan FX, Hewett JE. The importance of enhancing self-efficacy in rheumatoid arthritis. Arthritis Care Res, 1997; 10: 18-26.
39. Katz PP, Yelin EH. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J Rheumatol, 1993; 20: 790-6.
40. Berkanovic E, Hurwicz ML, Lachenbruch PA. Concordant and discrepant views of patients' physical functioning. Arthritis Care Res, 1995; 8: 94-101.
41. Clemmey PA, Nicassio PM. Illness self-schemas in depressed and nondepressed rheumatoid arthritis patients. J Behav Med, 1997; 20: 273-90.
42. Li X, Gignac MA, Anis AH. Workplace, psychosocial factors, and depressive symptoms among working people with arthritis: a longitudinal study. J Rheumatol, 2006; 33: 1849-55.
43. Margaretten M, Barton J, Julian L, Katz P, Trupin L, Tonner C, Graf J, Imboden J, Yelin E. Socioeconomic determinants of disability and depression in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken), 2011; 63: 240-6.
44. Treharne GJ, Lyons AC, Kitas GD. Adherence to medication. N Engl J Med, 2005; 353: 1972-4; author reply 1972-4.
45. Scherrer JF, Virgo KS, Zeringue A, Bucholz KK, Jacob T, Johnson RG, True WR, Carney RM, Freedland KE, Xian H, Caplan L, McDonald J, Eisen SA. Depression increases risk of incident myocardial infarction among Veterans Administration patients with rheumatoid arthritis. Gen Hosp Psychiatry, 2009; 31: 353-9.
46. Clement ND, Breusch SJ, Biant LC. Lower limb joint replacement in rheumatoid arthritis. J Orthop Surg Res, 2012; 7: 27.
47. Gibney SM, Drexhage HA. Evidence for a Dysregulated Immune System in the Etiology of Psychiatric Disorders. J Neuroimmune Pharmacol, 2013; 8: 900-20.
48. Muller R, Kallikorm R, Polluste K, Lember M. Compliance with treatment of rheumatoid arthritis. Rheumatol Int, 2012; 32: 3131-5.
49. Hou R, Baldwin DS. A neuroimmunological perspective on anxiety disorders. Hum Psychopharmacol, 2012; 27: 6-14.
50. Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, Lanctot KL. A meta-analysis of cytokines in major depression. Biol Psychiatry, 2010; 67: 446-57.
51. Musselman DL, Miller AH, Porter MR, Manatunga A, Gao F, Penna S, Pearce BD, Landry J, Glover S, McDaniel JS, Nemeroff CB. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry, 2001; 158: 1252-7.
52. Danner M, Kasl SV, Abramson JL, Vaccarino V. Association between depression and elevated C-reactive protein. Psychosom Med, 2003; 65: 347-56.
53. Lanquillon S, Krieg JC, Bening-Abu-Shach U, Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology, 2000; 22: 370-9.
54. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl), 2003; 170: 429-33.
55. Glaser R, Robles TF, Sheridan J, Malarkey WB, Kiecolt-Glaser JK. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiatry, 2003; 60: 1009-14.
56. Dellagioia N, Devine L, Pittman B, Hannestad J. Bupropion pretreatment of endotoxin-induced depressive symptoms. Brain Behav Immun, 2013; 31: 197-204.
57. O'Connor JC, Andre C, Wang Y, Lawson MA, Szegedi SS, Lestage J, Castanon N, Kelley KW, Dantzer R. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J Neurosci, 2009; 29: 4200-9.
58. Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol, 2006; 21: 227-31.
59. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Moller HJ, Arolt V, Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry, 2006; 11: 680-4.
60. Martino M, Rocchi G, Escelsior A, Fornaro M. Immunomodulation Mechanism of Antidepressants: Interactions between Serotonin/ Norepinephrine Balance and Th1/Th2 Balance. Curr Neuropharmacol, 2012; 10: 97-123.
61. Antonioli M, Rybka J, Carvalho LA. Neuroimmune endocrine effects of antidepressants. Neuropsychiatr Dis Treat, 2012; 8: 65-83.
62. Baharav E, Bar-Yehuda S, Madi L, Silberman D, Rath-Wolfson L, Halpren M, Ochaion A, Weinberger A, Fishman P. Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models. J Rheumatol, 2005; 32: 469-76.
63. Yuan XQ, Qiu G, Liu XJ, Liu S, Wu Y, Wang X, Lu T. Fluoxetine promotes remission in acute experimental autoimmune encephalomyelitis in rats. Neuroimmunomodulation, 2012; 19: 201-8.
64. Krishnadas R, Cavanagh J. Sustained remission of rheumatoid arthritis with a specific serotonin reuptake inhibitor antidepressant: a case report and review of the literature. J Med Case Rep, 2011; 5: 112.
65. Bouhuys AL, Flentge F, Oldehinkel AJ, van den Berg MD. Potential psychosocial mechanisms linking depression to immune function in elderly subjects. Psychiatry Res, 2004; 127: 237-45.
66. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, Lalla D, Woolley M, Jahreis A, Zitnik R, Cella D, Krishnan R. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet, 2006; 367: 29-35.
67. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol, 2006; 27: 24-31.
68. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry, 2003; 160: 1554-65.
69. Claes SJ. CRH, stress, and major depression: a psychobiological interplay. Vitam Horm, 2004; 69: 117-50.
70. Barden N. Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression. J Psychiatry Neurosci, 2004; 29: 185-93.
71. Miller GE, Cohen S, Ritchey AK. Chronic psychological stress and the regulation of pro-inflammatory cytokines: a glucocorticoidresistance model. Health Psychol, 2002; 21: 531-41.
72. Davis MC, Zautra AJ, Younger J, Motivala SJ, Attrep J, Irwin MR. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. Brain Behav Immun, 2008; 22: 24-32.
73. Peiffer A, Veilleux S, Barden N. Antidepressant and other centrally acting drugs regulate glucocorticoid receptor messenger RNA levels in rat brain. Psychoneuroendocrinology, 1991; 16: 505-15.
74. Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry, 2001; 49: 391-404.
75. Hallam KT, Smith DI, Berk M. Differences between subjective and objective assessments of the utility of Electroconvulsive therapy in patients with bipolar and unipolar depression. J Affect Disord, 2009; 112: 212-8.
76. Juruena MF, Pariante CM, Papadopoulos AS, Poon L, Lightman S, Cleare AJ. Prednisolone suppression test in depression: prospective study of the role of HPA axis dysfunction in treatment resistance. Br J Psychiatry, 2009; 194: 342-9.
77. Kalyoncu U, Dougados M, Daures JP, Gossec L. Reporting of patient-reported outcomes in recent trials in rheumatoid arthritis: a systematic literature review. Ann Rheum Dis, 2009; 68: 183-90.
78. Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, Carmona L, Daures JP, de Wit M, Dijkmans BA, Englbrecht M, Gunendi Z, Heiberg T, Kirwan JR, Mola EM, Matucci-Cerinic M, Otsa K, Schett G, Sokka T, Wells GA, Aanerud GJ, Celano A, Dudkin A, Hernandez C, Koutsogianni K, Akca FN, Petre AM, Richards P, Scholte-Voshaar M, Von Krause G, Kvien TK. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis, 2009; 68: 1680-5.
79. Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, de Wit M, Dijkmans BA, Dougados M, Englbrecht M, Gogus F, Heiberg T, Hernandez C, Kirwan JR, Mola EM, Cerinic MM, Otsa K, Schett G, Scholte-Voshaar M, Sokka T, von Krause G, Wells GA, Kvien TK. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis, 2011; 70: 935-42.
80. Wolfe F, Michaud K, Li T. Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. J Rheumatol, 2006; 33: 1942-51.
81. Kojima M, Kojima T, Ishiguro N, Oguchi T, Oba M, Tsuchiya H, Sugiura F, Furukawa TA, Suzuki S, Tokudome S. Psychosocial factors, disease status, and quality of life in patients with rheumatoid arthritis. J Psychosom Res, 2009; 67: 425-31.
82. Klauenberg S, Maier C, Assion HJ, Hoffmann A, Krumova EK, Magerl W, Scherens A, Treede RD, Juckel G. Depression and changed pain perception: hints for a central disinhibition mechanism. Pain, 2008; 140: 332-43.
83. Bardin L, Malfetes N, Newman-Tancredi A, Depoortere R. Chronic restraint stress induces mechanical and cold allodynia, and enhances inflammatory pain in rat: Relevance to human stressassociated painful pathologies. Behav Brain Res, 2009; 205: 360-6.
84. Rosenberger PH, Kerns R, Jokl P, Ickovics JR. Mood and attitude predict pain outcomes following arthroscopic knee surgery. Ann Behav Med, 2009; 37: 70-6.
85. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum, 2000; 43: 2751-61.
86. Katz PP, Yelin EH. Activity loss and the onset of depressive symptoms: do some activities matter more than others? Arthritis Rheum, 2001; 44: 1194-202.
87. Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford), 2006; 45: 885-9.
88. Belza BL, Henke CJ, Yelin EH, Epstein WV, Gilliss CL. Correlates of fatigue in older adults with rheumatoid arthritis. Nurs Res, 1993; 42: 93-9.
89. Chauffier K, Salliot C, Berenbaum F, Sellam J. Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford), 2012; 51: 60-8.
90. Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GA. Impact of fatigue on health-related quality of life in rheumatoid arthritis. Arthritis Rheum, 2004; 51: 578-85.
91. Wolfe F, Michaud K. Fatigue, rheumatoid arthritis, and anti-tumor necrosis factor therapy: an investigation in 24,831 patients. J Rheumatol, 2004; 31: 2115-20.
92. Huyser BA, Parker JC, Thoreson R, Smarr KL, Johnson JC, Hoffman R. Predictors of subjective fatigue among individuals with rheumatoid arthritis. Arthritis Rheum, 1998; 41: 2230-7.
93. Ozcetin A, Ataoglu S, Kocer E, Yazici S, Yildiz O, Ataoglul A, Icmeli C. Effects of depression and anxiety on quality of life of patients with rheumatoid arthritis, knee osteoarthritis and fibromyalgia syndrome. West Indian Med J, 2007; 56: 122-9.
94. Tander B, Cengiz K, Alayli G, Ilhanli I, Canbaz S, Canturk F. A comparative evaluation of health related quality of life and depression in patients with fibromyalgia syndrome and rheumatoid arthritis. Rheumatol Int, 2008; 28: 859-65.
95. Persson LO, Berglund K, Sahlberg D. Psychological factors in chronic rheumatic diseases--a review. The case of rheumatoid arthritis, current research and some problems. Scand J Rheumatol, 1999; 28: 137-44.
96. Power JD, Perruccio AV, Badley EM. Pain as a mediator of sleep problems in arthritis and other chronic conditions. Arthritis Rheum, 2005; 53: 911-9.
97. Lee YC, Chibnik LB, Lu B, Wasan AD, Edwards RR, Fossel AH, Helfgott SM, Solomon DH, Clauw DJ, Karlson EW. The relationship between disease activity, sleep, psychiatric distress and pain sensitivity in rheumatoid arthritis: a cross-sectional study. Arthritis Res Ther, 2009; 11: R160.
98. Luyster FS, Chasens ER, Wasko MC, Dunbar-Jacob J. Sleep quality and functional disability in patients with rheumatoid arthritis. J Clin Sleep Med, 2011; 7: 49-55.
99. Nicassio PM, Wallston KA. Longitudinal relationships among pain, sleep problems, and depression in rheumatoid arthritis. J Abnorm Psychol, 1992; 101: 514-20.
100. Moldofsky H. Rheumatic manifestations of sleep disorders. Curr Opin Rheumatol, 2010; 22: 59-63.
101. Folkman S, Moskowitz JT. Coping: pitfalls and promise. Annu Rev Psychol, 2004; 55: 745-74.
102. Connor-Smith JK, Flachsbart C. Relations between personality and coping: a meta-analysis. J Pers Soc Psychol, 2007; 93: 1080-107.
103. Covic T, Adamson B, Hough M. The impact of passive coping on rheumatoid arthritis pain. Rheumatology (Oxford), 2000; 39: 1027-30.
104. Treharne GJ, Lyons AC, Booth DA, Kitas GD. Psychological wellbeing across 1 year with rheumatoid arthritis: coping resources as buffers of perceived stress. Br J Health Psychol, 2007; 12: 323-45.
105. Newman S, Mulligan K. The psychology of rheumatic diseases. Baillieres Best Pract Res Clin Rheumatol, 2000; 14: 773-86.
106. Ramjeet J, Koutantji M, Barrett EM, Scott DG. Coping and psychological adjustment in recent-onset inflammatory polyarthritis: the role of gender and age. Rheumatology (Oxford), 2005; 44: 1166-8.
107. Sturgeon JA, Zautra AJ. State and trait pain catastrophizing and emotional health in rheumatoid arthritis. Ann Behav Med, 2013; 45: 69-77.
108. Edwards RR, Cahalan C, Mensing G, Smith M, Haythornthwaite JA. Pain, catastrophizing, and depression in the rheumatic diseases. Nat Rev Rheumatol, 2011; 7: 216-24.
109. Marcenaro M, Prete C, Badini A, Sulli A, Magi E, Cutolo M. Rheumatoid arthritis, personality, stress response style, and coping with illness. A preliminary survey. Ann N Y Acad Sci, 1999; 876: 419-25.
110. Zeidner M AA, Saklofske DHZ M., & Saklofske, D.H. Adaptive and maladaptive coping.Handbook of Coping: Theory, Research and Applications. John Wiley: New York 1996.
111. Crisson JE, Keefe FJ. The relationship of locus of control to pain coping strategies and psychological distress in chronic pain patients. Pain, 1988; 35: 147-54.
112. Gustafsson M, Gaston-Johansson F. Pain intensity and health locus of control: a comparison of patients with fibromyalgia syndrome and rheumatoid arthritis. Patient Educ Couns, 1996; 29: 179-88.
113. Cross MJ, March LM, Lapsley HM, Byrne E, Brooks PM. Patient self-efficacy and health locus of control: relationships with health status and arthritis-related expenditure. Rheumatology (Oxford), 2006; 45: 92-6.
114. Knittle KP, De Gucht V, Hurkmans EJ, Vlieland TP, Peeters AJ, Ronday HK, Maes S. Effect of self-efficacy and physical activity goal achievement on arthritis pain and quality of life in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken), 2011; 63: 1613-9.
115. Bussing A, Michalsen A, Balzat HJ, Grunther RA, Ostermann T, Neugebauer EA, Matthiessen PF. Are spirituality and religiosity resources for patients with chronic pain conditions? Pain Med, 2009; 10: 327-39.
116. Lin WC, Gau ML, Lin HC, Lin HR. Spiritual well-being in patients with rheumatoid arthritis. J Nurs Res, 2011; 19: 1-12.
117. Tillmann T, Krishnadas R, Cavanagh J, Petrides K. Possible rheumatoid arthritis subtypes in terms of rheumatoid factor, depression, diagnostic delay and emotional expression: an exploratory casecontrol study. Arthritis Res Ther, 2013; 15: R45.
118. Smolen JS. Efficacy and safety of the new DMARD leflunomide: comparison to placebo and sulfasalazine in active rheumatoid arthritis. Scand J Rheumatol Suppl, 1999; 112: 15-21.
119. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med, 2000; 343: 1594-602.
120. Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis, 2008; 67: 1716-23.
121. Kaptchuk TJ. The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Ann Intern Med, 2002; 136: 817-25.
122. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med, 2010; 363: 1303-12.
123. Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar Pinheiro G, Lazovskis J, Hetland ML, Peets T, Immonen K, Maillefert JF, Drosos AA, Alten R, Pohl C, Rojkovich B, Bresnihan B, Minnock P, Cazzato M, Bombardieri S, Rexhepi S, Rexhepi M, Andersone D, Stropuviene S, Huisman M, Sierakowski S, Karateev D, Skakic V, Naranjo A, Baecklund E, Henrohn D, Gogus F, Badsha H, Mofti A, Taylor P, McClinton C, Yazici Y. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis, 2009; 68: 1666-72.
124. Vase L, Riley JL, 3rd, Price DD. A comparison of placebo effects in clinical analgesic trials versus studies of placebo analgesia. Pain, 2002; 99: 443-52.
125. Faria V, Fredrikson M, Furmark T. Imaging the placebo response: a neurofunctional review. Eur Neuropsychopharmacol, 2008; 18: 473-85.
126. Meissner K, Bingel U, Colloca L, Wager TD, Watson A, Flaten MA. The placebo effect: advances from different methodological approaches. J Neurosci, 2011; 31: 16117-24.
127. Papadopoulos D, Mitsikostas DD. A meta-analytic approach to estimating nocebo effects in neuropathic pain trials. J Neurol, 2012; 259: 436-47.
128. Di Blasi Z, Harkness E, Ernst E, Georgiou A, Kleijnen J. Influence of context effects on health outcomes: a systematic review. Lancet, 2001; 357: 757-62.
129. Odegard S, Finset A, Mowinckel P, Kvien TK, Uhlig T. Pain and psychological health status over a 10-year period in patients with recent onset rheumatoid arthritis. Ann Rheum Dis, 2007; 66: 1195-201.
130. Bremmer MA, Beekman AT, Deeg DJ, Penninx BW, Dik MG, Hack CE, Hoogendijk WJ. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord, 2008; 106: 249-55.
131. Bijlsma JW, Huiskes CJ, Kraaimaat FW, Vanderveen MJ, Huber-Bruning O. Relation between patients' own health assessment and clinical and laboratory findings in rheumatoid arthritis. J Rheumatol, 1991; 18: 650-3.
132. Margaretten M, Yelin E, Imboden J, Graf J, Barton J, Katz P, Julian L. Predictors of depression in a multiethnic cohort of patients with rheumatoid arthritis. Arthritis Rheum, 2009; 61: 1586-91.
133. Ho RC, Fu EH, Chua AN, Cheak AA, Mak A. Clinical and psychosocial factors associated with depression and anxiety in Singaporean patients with rheumatoid arthritis. Int J Rheum Dis, 2011; 14: 37-47.
134. Tuncay R, Eksioglu E, Cakir B, Gurcay E, Cakci A. Factors affecting drug treatment compliance in patients with rheumatoid arthritis. Rheumatol Int, 2007; 27: 743-6.
135. Bendtsen P, Akerlind I, Hornquist JO. Pharmacological intervention in older patients with rheumatoid arthritis. Quality of life aspects. Drugs Aging, 1995; 7: 338-46.
136. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med, 2000; 160: 2101-7.
137. Brus H, van de Laar M, Taal E, Rasker J, Wiegman O. Compliance in rheumatoid arthritis and the role of formal patient education. Semin Arthritis Rheum, 1997; 26: 702-10.
138. Garcia-Gonzalez A, Richardson M, Garcia Popa-Lisseanu M, Cox V, Kallen MA, Janssen N, Ng B, Marcus DM, Reveille JD, Suarez-Almazor ME. Treatment adherence in patients with rheumatoid arthritis and systemic lupus erythematosus. Clin Rheumatol, 2008; 27: 883-9.
139. Kumar K, Gordon C, Toescu V, Buckley CD, Horne R, Nightingale PG, Raza K. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and White British origin. Rheumatology (Oxford), 2008; 47: 690-7.
140. Savard M. Bridging the communication gap between physicians and their patients with physical symptoms of depression. Prim Care Companion J Clin Psychiatry, 2004; 6: 17-24.
141. Porter LS, Keefe FJ, Wellington C, de Williams A. Pain communication in the context of osteoarthritis: patient and partner selfefficacy for pain communication and holding back from discussion of pain and arthritis-related concerns. Clin J Pain, 2008; 24: 662-8.
142. Keefe FJ, Shelby RA, Somers TJ. Catastrophizing and pain coping: moving forward. Pain, 2010; 149: 165-6.
143. Kool MB, van Middendorp H, Boeije HR, Geenen R. Understanding the lack of understanding: invalidation from the perspective of the patient with fibromyalgia. Arthritis Rheum, 2009; 61: 1650-6.
144. Gleason ME, Iida M, Bolger N, Shrout PE. Daily supportive equity in close relationships. Pers Soc Psychol Bull, 2003; 29: 1036-45.
145. Montoya P, Larbig W, Braun C, Preissl H, Birbaumer N. Influence of social support and emotional context on pain processing and magnetic brain responses in fibromyalgia. Arthritis Rheum, 2004; 50: 4035-44.
146. Penninx BW, van Tilburg T, Deeg DJ, Kriegsman DM, Boeke AJ, van Eijk JT. Direct and buffer effects of social support and personal coping resources in individuals with arthritis. Soc Sci Med, 1997; 44: 393-402.
147. Yazici Y, Abramson SB. Rheumatoid arthritis treatment and monitoring of outcomes--where are we [corrected] in 2007? Bull NYU Hosp Jt Dis, 2007; 65: 300-5.
148. Barton JL, Trupin L, Schillinger D, Gansky SA, Tonner C, Margaretten M, Chernitskiy V, Graf J, Imboden J, Yelin E. Racial and ethnic disparities in disease activity and function among persons with rheumatoid arthritis from university-affiliated clinics. Arthritis Care Res (Hoboken), 2011; 63: 1238-46.
149. Bradley LA, Young LD, Anderson KO, Turner RA, Agudelo CA, McDaniel LK, Pisko EJ, Semble EL, Morgan TM. Effects of psychological therapy on pain behavior of rheumatoid arthritis patients. Treatment outcome and six-month followup. Arthritis Rheum, 1987; 30: 1105-14.
150. Parker JC, Smarr KL, Slaughter JR, Johnston SK, Priesmeyer ML, Hanson KD, Johnson GE, Hewett JE, Irvin WS, Komatireddy GR, Walker SE. Management of depression in rheumatoid arthritis: a combined pharmacologic and cognitive-behavioral approach. Arthritis Rheum, 2003; 49: 766-77.
151. Astin JA, Beckner W, Soeken K, Hochberg MC, Berman B. Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum, 2002; 47: 291-302.
152. Dixon KE, Keefe FJ, Scipio CD, Perri LM, Abernethy AP. Psychological interventions for arthritis pain management in adults: a meta-analysis. Health Psychol, 2007; 26: 241-50.
153. Sharpe L, Allard S, Sensky T. Five-year followup of a cognitivebehavioral intervention for patients with recently-diagnosed rheumatoid arthritis: effects on health care utilization. Arthritis Rheum, 2008; 59: 311-6.
154. Vriezekolk JE, Eijsbouts AM, van Lankveld WG, Beenackers H, Geenen R, van den Ende CH. An acceptance-oriented cognitivebehavioral therapy in multimodal rehabilitation: A pre-post test evaluation in highly distressed patients with rheumatic diseases. Patient Educ Couns, 2013; 91: 357-63.
155. Doherty M, Dieppe P. The "placebo" response in osteoarthritis and its implications for clinical practice. Osteoarthritis Cartilage, 2009; 17: 1255-62.
156. McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes. A critical review. Arch Intern Med, 1997; 157: 1921-9.
157. Irvine J, Baker B, Smith J, Jandciu S, Paquette M, Cairns J, Connolly S, Roberts R, Gent M, Dorian P. Poor adherence to placebo or amiodarone therapy predicts mortality: results from the CAMIAT study. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. Psychosom Med, 1999; 61: 566-75.
158. Gettings L. Psychological well-being in rheumatoid arthritis: a review of the literature. Musculoskeletal Care, 2010; 8: 99-106.
159. Iversen MD, Hammond A, Betteridge N. Self-management of rheumatic diseases: state of the art and future perspectives. Ann Rheum Dis, 2010; 69: 955-63.
160. Bijsterbosch J, Scharloo M, Visser AW, Watt I, Meulenbelt I, Huizinga TW, Kaptein AA, Kloppenburg M. Illness perceptions in patients with osteoarthritis: change over time and association with disability. Arthritis Rheum, 2009; 61: 1054-61.
161. Ryan RM, Deci EL. Self-determination theory and the facilitation of intrinsic motivation, social development, and well-being. Am Psychol, 2000; 55: 68-78.
162. Rollnick S MW, Butler CC. Motivational interviewing in health care. Helping Patients change bahavior. 2008. The Guilford Press; 1st edition.
163. Hawks SR, Hull ML, Thalman RL, Richins PM. Review of spiritual health: definition, role, and intervention strategies in health promotion. Am J Health Promot, 1995; 9: 371-8.
164. Thieme K, Flor H, Turk DC. Psychological pain treatment in fibromyalgia syndrome: efficacy of operant behavioural and cognitive behavioural treatments. Arthritis Res Ther, 2006; 8: R121.
165. Keefe FJ, Van Horn Y. Cognitive-behavioral treatment of rheumatoid arthritis pain: maintaining treatment gains. Arthritis Care Res, 1993; 6: 213-22.
166. Brus HL, Taal E, van de Laar MA, Rasker JJ, Wiegman O. Patient education and disease activity: a study among rheumatoid arthritis patients. Arthritis Care Res, 1997; 10: 320-4.
167. de Klerk E, van der Heijde D, Landewe R, van der Tempel H, van der Linden S. The compliance-questionnaire-rheumatology compared with electronic medication event monitoring: a validation study. J Rheumatol, 2003; 30: 2469-75.
168. Bandura A, Adams NE, Beyer J. Cognitive processes mediating behavioral change. J Pers Soc Psychol, 1977; 35: 125-39.
169. Martin LR, Williams SL, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag, 2005; 1: 189-99.
170. Jin J, Sklar GE, Min Sen Oh V, Chuen Li S. Factors affecting therapeutic compliance: A review from the patient's perspective. Ther Clin Risk Manag, 2008; 4: 269-86.
171. Ra E. Poor adherence to medication in adults with rheumatoid arthritis-Reasons and solutions. Disease Management & Health Outcomes 2008;16:13-29. 2008.
172. Kool MB, van Middendorp H, Lumley MA, Schenk Y, Jacobs JW, Bijlsma JW, Geenen R. Lack of understanding in fibromyalgia and rheumatoid arthritis: the Illness Invalidation Inventory (3*I). Ann Rheum Dis, 2010; 69: 1990-5.
173. Ra E. Poor adherence to medication in adults with rheumatoid arthritis: reasons and solutions. Dis Manage Health Outcomes. 2008; 16: 13-29.
174. Sanderson T, Kirwan J. Patient-reported outcomes for arthritis: time to focus on personal life impact measures? Arthritis Rheum, 2009; 61: 1-3.
175. Sanderson TC, Hewlett SE, Flurey C, Dures E, Richards P, Kirwan JR. The impact triad (severity, importance, self-management) as a method of enhancing measurement of personal life impact of rheumatic diseases. In: ed.^eds., J Rheumatol: Canada, 2011; pp. 191-4.